Alaunos Updates Governance, Ends Cantor Advisory Agreement

Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potentialAn update from Alaunos Therapeutics ( (TCRT) ) is now available. On January 8, 2026, Alaunos Therapeutics terminated, with immediate effect, its exclusive financial advisory engagement with Cantor Fitzgerald related to potential strategic transactions, citing a contractual right to end the agreement after 12 months without incurring termination fees, and separately adopted amended and restated bylaws that tighten and modernize stockholder nomination and meeting procedures, including detailed advance-notice and disclosure requirements and enhanced authority for meeting chairs to disregard non-compliant proposals. The company also disclosed escalating activism from a shareholder group that amassed about 8.6% of its stock in late 2025 and has formally proposed industry executive Gerald W. Bruce for a board seat, a nomination now under review by the governance committee, while simultaneously reporting encouraging proof-of-concept preclinical data from a lead non-hormonal obesity compound in diet-induced obese mice and warning that, with just $1.9 million in cash as of September 30, 2025 and a runway only into the first quarter of 2026, it must secure new financing by the end of that quarter to sustain operations and advance its obesity program into IND-enabling studies. Spark’s Take on TCRT Stock According to Spark, TipRanks’ AI Analyst, TCRT is a Neutral. Alaunos Therapeutics’ overall score is primarily impacted by its weak financial performance with ongoing losses and negative cash flows. While the technical analysis shows some positive momentum, the negative P/E ratio and lack of dividends underscore valuation challenges. The absence of earnings call and corporate events information further limits the stock’s appeal. To see Spark’s full report on TCRT stock, click here. More about Alaunos Therapeutics Alaunos Therapeutics is a biotechnology company developing small-molecule therapies for obesity and related metabolic disorders, with a focus on orally administered drugs that aim to offer a differentiated, non-hormonal mechanism of action versus current hormone-based weight-loss treatments. Average Trading Volume: 445,596 Technical Sentiment Signal: Sell Current Market Cap: $7.14M For an in-depth examination of TCRT stock, go to TipRanks’ Overview page.